133 related articles for article (PubMed ID: 22130104)
1. Pharmacokinetics and pharmacodynamics of oral tolvaptan administered in 15- to 60-mg single doses to healthy Korean men.
Yi S; Jeon H; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Cardiovasc Pharmacol; 2012 Apr; 59(4):315-22. PubMed ID: 22130104
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers.
Kim SR; Hasunuma T; Sato O; Okada T; Kondo M; Azuma J
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S5-17. PubMed ID: 22120090
[TBL] [Abstract][Full Text] [Related]
3. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Br J Clin Pharmacol; 2012 Apr; 73(4):579-87. PubMed ID: 21988334
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects.
Shoaf SE; Wang Z; Bricmont P; Mallikaarjun S
J Clin Pharmacol; 2007 Dec; 47(12):1498-507. PubMed ID: 17925589
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects.
Shoaf SE; Kim SR; Bricmont P; Mallikaarjun S
Eur J Clin Pharmacol; 2012 Dec; 68(12):1595-603. PubMed ID: 22585285
[TBL] [Abstract][Full Text] [Related]
6. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects.
Shoaf SE; Bricmont P; Mallikaarjun S
Int J Clin Pharmacol Ther; 2012 Feb; 50(2):150-6. PubMed ID: 22257581
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function.
Shoaf SE; Bricmont P; Mallikaarjun S
Kidney Int; 2014 Apr; 85(4):953-61. PubMed ID: 24048380
[TBL] [Abstract][Full Text] [Related]
8. Phase III clinical pharmacology study of tolvaptan.
Inomata T; Izumi T; Matsuzaki M; Hori M; Hirayama A;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S57-65. PubMed ID: 22120094
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide.
Shoaf SE; Bramer SL; Bricmont P; Zimmer CA
J Cardiovasc Pharmacol; 2007 Aug; 50(2):213-22. PubMed ID: 17703139
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.
Shoaf SE; Chapman AB; Torres VE; Ouyang J; Czerwiec FS
J Clin Pharmacol; 2017 Jul; 57(7):906-917. PubMed ID: 28218410
[TBL] [Abstract][Full Text] [Related]
11. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
Wang YF; Tang JT; Han T; Ding HG; Ye WJ; Wang MR; Cheng J; Yang YP; Chen CW; Xie Q; Mao Q; Niu JQ; Wang ZH; Wei Z; Chen YX; Zeng M; Mao YM
J Dig Dis; 2018 Mar; 19(3):144-154. PubMed ID: 29389068
[TBL] [Abstract][Full Text] [Related]
12. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
[TBL] [Abstract][Full Text] [Related]
13. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of OPC-61815, a Prodrug of Tolvaptan for Intravenous Administration, in Patients With Congestive Heart Failure - A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial.
Sato N; Uno S; Yamasaki Y; Hirano T; Kim S;
Circ J; 2022 Mar; 86(4):699-708. PubMed ID: 34511586
[TBL] [Abstract][Full Text] [Related]
15. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two doses and dosing regimens of tolvaptan in congestive heart failure.
Hauptman PJ; Zimmer C; Udelson J; Shoaf SE; Mallikaarjun S; Bramer SL; Orlandi C
J Cardiovasc Pharmacol; 2005 Nov; 46(5):609-14. PubMed ID: 16220067
[TBL] [Abstract][Full Text] [Related]
17. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
Shoaf SE; Bricmont P; Dandurand A
Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
[TBL] [Abstract][Full Text] [Related]
18. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
19. Short-Term Tolvaptan Increases Water Intake and Effectively Decreases Urinary Calcium Oxalate, Calcium Phosphate and Uric Acid Supersaturations.
Cheungpasitporn W; Erickson SB; Rule AD; Enders F; Lieske JC
J Urol; 2016 May; 195(5):1476-1481. PubMed ID: 26598423
[TBL] [Abstract][Full Text] [Related]
20. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Vaghasiya RP; DeVita MV; Michelis MF
Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
